Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Illumina is a diagnostics & research business based in the US. Illumina shares (ILMN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $143.82 – an increase of 6.53% over the previous week. Illumina employs 10,590 staff and has a trailing 12-month revenue of around $4.4 billion.
| Latest market close | $143.82 |
|---|---|
| 52-week range | $90.96 - $156.66 |
| 50-day moving average | $140.18 |
| 200-day moving average | $125.37 |
| Wall St. target price | $164.60 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-9.97 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $140.14 from 2024-11-22
| 1 week (2024-11-19) | 3.81% |
|---|---|
| 1 month (2024-10-25) | -1.28% |
| 3 months (2024-08-26) | 7.45% |
| 6 months (2024-05-24) | 31.61% |
| 1 year (2023-11-24) | 42.51% |
|---|---|
| 2 years (2022-11-25) | -34.21% |
| 3 years (2021-11-26) | 359.7179 |
| 5 years (2019-11-26) | 310.7101 |
Valuing Illumina stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Illumina's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6167. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Illumina's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Illumina's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $730 million.
The EBITDA is a measure of a Illumina's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.4 billion |
|---|---|
| Operating margin TTM | 23.98% |
| Gross profit TTM | $3.1 billion |
| Return on assets TTM | 2.62% |
| Return on equity TTM | -39.51% |
| Profit margin | -36.11% |
| Book value | $13.45 |
| Market Capitalization | $21.7 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Illumina.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 9.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Illumina's overall score of 9.18 (as at 12/31/2018) is excellent – landing it in it in the 2nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Illumina is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 2.22/100
Illumina's environmental score of 2.22 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 2.6/100
Illumina's social score of 2.6 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Illumina is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.36/100
Illumina's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Illumina is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Illumina scored a 1 out of 5 for controversy – the highest score possible, reflecting that Illumina has managed to keep its nose clean.
Illumina Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 9.18 |
|---|---|
| Total ESG percentile | 2.42 |
| Environmental score | 2.22 |
| Environmental score percentile | 2 |
| Social score | 2.6 |
| Social score percentile | 2 |
| Governance score | 5.36 |
| Governance score percentile | 2 |
| Level of controversy | 1 |
We're not expecting Illumina to pay a dividend over the next 12 months.
Illumina's shares were split on a 1028:1000 basis on 24 June 2024 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1028 shares. This wouldn't directly have changed the overall worth of your Illumina shares – just the quantity. However, indirectly, the new 2.7% lower share price could have impacted the market appetite for Illumina shares which in turn could have impacted Illumina's share price.
Over the last 12 months, Illumina's shares have ranged in value from as little as $90.963 up to $156.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Illumina's is 1.131. This would suggest that Illumina's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.